<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21496066</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>02</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1365-2125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>72</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.</ArticleTitle>
            <Pagination>
                <MedlinePgn>806-22</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2125.2011.03990.x</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To explore the opinions of patient reporters to the UK Yellow Card Scheme (YCS) on the importance of the scheme.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Postal questionnaires were distributed on our behalf to all patient reporters submitting a Yellow Card to the Medicines and Healthcare Regulatory Agency (MHRA) between March and December 2008, with one follow-up reminder to non-responders. Qualitative analysis was undertaken of responses to an open question asking why respondents felt patient reporting was important. This was followed up by telephone interviews with a purposive sample of selected respondents.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 1362 evaluable questionnaires returned from 2008 distributed (68%) and 1238 (91%) respondents provided a total of 1802 comments. Twenty-seven interviews were conducted, which supported and expanded the views expressed in the questionnaire. Four main themes emerged, indicating views that the YCS was of importance to pharmacovigilance in general, manufacturers and licensing authorities, patients and the public and health professionals. Reporters viewed the YCS as an important opportunity to describe their experiences for the benefit of others and to contribute to pharmacovigilance. The scheme's independence from health professionals was regarded as important, in part to provide the patient perspective to manufacturers and regulators, but also because of dismissive attitudes and under-reporting by health professionals.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Direct patient reporting through the YCS is viewed as important by those who have used the scheme, in order to provide the patient experience for the benefit of pharmacovigilance, as an independent perspective from those of health professionals.</AbstractText>
                <CopyrightInformation>© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Anderson</LastName>
                    <ForeName>Claire</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Nottingham, Nottingham, UK. claire.anderson@nottingham.ac.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krska</LastName>
                    <ForeName>Janet</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murphy</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Avery</LastName>
                    <ForeName>Anthony</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Yellow Card Study Collaboration</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName>
                <QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName>
                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010358" MajorTopicYN="N">Patient Participation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010361" MajorTopicYN="N">Patients</DescriptorName>
                <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012923" MajorTopicYN="N">Social Class</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21496066</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2011.03990.x</ArticleId>
            <ArticleId IdType="pmc">PMC3243015</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Opin Drug Saf. 2004 Jul;3(4):363-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15268652</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Clin Pharmacol. 2009 Jan;65(1):43-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18825377</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Clin Pharmacol. 2010 Nov;66(11):1143-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20658130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):21-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15073801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 2002 Mar;53(3):318-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11874396</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Epidemiol. 2002 Sep;55(9):945-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12393084</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Clin Pharmacol. 2000 Dec;56(9-10):729-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11214784</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Saf. 2003;26(4):211-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12608885</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Clin Pharmacol. 2007 Feb;63(2):148-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17274788</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Mar 11;362(10):865-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20220181</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Pharmacother. 2010 May;44(5):936-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20388861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Technol Assess. 2011 May;15(20):1-234, iii-iv</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21545758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacoepidemiol Drug Saf. 2011 May;20(5):523-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21328634</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Saf. 2007;30(8):669-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17696579</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
